Zaiou M, Azrolan N, Hayek T, Wang H, Wu L, Haghpassand M, Cizman B, Madaio M P, Milbrandt J, Marsh J B, Breslow J L, Fisher E A
Department of Biochemistry, Medical College of Pennsylvania - Hahnemann School of Medicine, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania 19129, USA.
J Clin Invest. 1998 Apr 15;101(8):1699-707. doi: 10.1172/JCI2166.
To identify molecular factors regulating apo A-I production in vivo, we induced in transgenic mice the experimental nephrotic syndrome, which results in elevated levels of HDL cholesterol (HDL-C), plasma apo A-I, and hepatic apo A-I mRNA. Human (h) apo A-I transgenic mice with different length 5' flanking sequences (5.5 or 0.256 kb, the core promoter for hepatic-specific basal expression) were injected with nephrotoxic (NTS) or control serum. With nephrosis, there were comparable (greater than twofold) increases in both lines of HDL-C, h-apo A-I, and hepatic h-apo A-I mRNA, suggesting that cis-acting elements regulating induced apo A-I gene expression were within its core promoter. Hepatic nuclear extracts from control and nephrotic mice footprinted the core promoter similarly, implying that the same elements regulated basal and induced expression. Hepatic mRNA levels for hepatocyte nuclear factor (HNF) 4 and early growth response factor (EGR) 1, trans-acting factors that bind to the core promoter, were measured: HNF4 mRNA was not affected, but that of EGR-1 was elevated approximately fivefold in the nephrotic group. EGR-1 knockout (EGR1-KO) mice or mice expressing EGR-1 were injected with either NTS or control serum. Levels of HDL-C, apo A-I, and hepatic apo A-I mRNA were lowest in nonnephrotic EGR1-KO mice and highest in nephrotic mice expressing EGR-1. Although in EGR1-KO mice HDL-C, apo A-I, and apo A-I mRNA levels also increased after NTS injection, they were approximately half of those in the nephrotic EGR-1-expressing mice. We conclude that in this model, basal and induced apo A-I gene expression in vivo are regulated by the trans-acting factor EGR-1 and require the same cis-acting elements in the core promoter.
为了确定体内调节载脂蛋白A-I(apo A-I)产生的分子因素,我们在转基因小鼠中诱导了实验性肾病综合征,该综合征导致高密度脂蛋白胆固醇(HDL-C)、血浆apo A-I和肝脏apo A-I mRNA水平升高。将具有不同长度5'侧翼序列(5.5或0.256 kb,肝脏特异性基础表达的核心启动子)的人(h)apo A-I转基因小鼠注射肾毒性(NTS)或对照血清。出现肾病时,两条品系的HDL-C、h-apo A-I和肝脏h-apo A-I mRNA均有相当程度(超过两倍)的增加,这表明调节诱导性apo A-I基因表达的顺式作用元件位于其核心启动子内。对照小鼠和肾病小鼠的肝脏核提取物对核心启动子的足迹分析结果相似,这意味着相同的元件调节基础表达和诱导表达。检测了与核心启动子结合的反式作用因子肝细胞核因子(HNF)4和早期生长反应因子(EGR)1的肝脏mRNA水平:HNF4 mRNA未受影响,但肾病组中EGR-1的mRNA升高了约五倍。将EGR-1基因敲除(EGR1-KO)小鼠或表达EGR-1的小鼠注射NTS或对照血清。非肾病EGR1-KO小鼠的HDL-C、apo A-I和肝脏apo A-I mRNA水平最低,而表达EGR-1的肾病小鼠中这些水平最高。尽管在EGR1-KO小鼠中,注射NTS后HDL-C、apo A-I和apo A-I mRNA水平也有所增加,但它们约为表达EGR-1的肾病小鼠中的一半。我们得出结论,在该模型中体内基础和诱导性apo A-I基因表达受反式作用因子EGR-1调节,并且在核心启动子中需要相同的顺式作用元件。